Lilly partners with JD Health to sell obesity and diabetes drugs directly in China

Eli Lilly has struck a deal with JD Health, an online pharmacy platform in China, to sell its obesity, type 2 diabetes and alopecia areata drugs directly to consumers there ^[1]. The partnership, announced on Lilly's WeChat channel on August 29, extends the company's direct-to-consumer sales approach, known as LillyDirect, into the Chinese market ^[1].

The new digital platform is meant to work as a "one-stop" shop for managing chronic disease, according to Lilly's announcement ^[1]. It will connect patients with online and in-person consultations with health care providers, handle prescriptions, and ship Lilly's drugs to patients ^[1]. The platform will also offer follow-up care for long-term disease management and include educational resources for both patients and health care professionals ^[1].

China represents a large potential market for these drugs. An estimated 148 million adults in China have diabetes, and more than 500 million are overweight or obese, according to figures cited in Lilly's announcement ^[1]. Those numbers point to major potential demand for Mounjaro (tirzepatide, for diabetes) and Zepbound (tirzepatide, for weight management), both of which have received Chinese regulatory approval ^[1].

The deal fits into a broader pattern of Lilly investment in China. The company appointed a new head of its Chinese business last year, and CEO David Ricks later met with China's commerce minister to discuss increased investment and research cooperation ^[1]. Lilly also announced in October a $200 million expansion of its manufacturing site in Suzhou, largely to meet rising demand for tirzepatide products ^[1]. Separately, Lilly's mazdutide, a dual GLP-1/glucagon receptor agonist licensed in China to Innovent Biologics, recently received a first-in-class approval there for chronic weight management ^[1].

Why it matters for patients

This deal is about China, not the United States, and it does not change how Americans buy Mounjaro, Zepbound, or any Lilly GLP-1 drug ^[1]. The source material notes that incretin drug prices in China are a fraction of US prices, which is part of what makes a direct-to-consumer channel there attractive to Lilly, but no specific China pricing figures are given in the announcement ^[1].

For US readers, the more relevant point may be what this signals about Lilly's broader direct-to-consumer strategy. Lilly has already built LillyDirect in the United States to let patients order its drugs and connect with telehealth providers online ^[1]. Extending that model to JD Health in China shows Lilly is investing in digital, direct sales channels as a company-wide approach, not just a US experiment ^[1]. Whether that strategy eventually affects how the company reaches patients in the US, including on pricing or access, is not addressed in the available reporting and is not yet known ^[1].

The deal also underscores how large the Chinese market is for these drugs. With close to 150 million adults with diabetes and more than half a billion people who are overweight or obese in China, the potential patient population dwarfs that of the United States ^[1]. That scale may shape how much manufacturing capacity and R&D investment Lilly directs toward China compared with other markets, though the sources do not specify any resulting shift in US supply ^[1].

What happens next

Lilly and JD Health say they plan to expand their collaboration to cover direct-to-consumer access and care services in more disease areas beyond diabetes, obesity and alopecia areata ^[1]. No specific timeline for that expansion is given in the announcement ^[1].